Skip to main content
Premium Trial:

Request an Annual Quote

Skyline Licenses TrovaGene Biomarker for AML

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Skyline Diagnostics has licensed rights to TrovaGene's NPM1 technology in Europe in a microarray test for use in helping guide acute myelogenous leukemia treatment, TrovaGene said today.

Skyline will use the TrovaGene nucleophosmin protein mutation, which is found in around 35 percent of AML patients and is associated with good disease prognosis, in its AMLprofiler in vitro diagnostic assay.

A three-day test, the AMLprofiler is used to reclassify more than 50 percent of intermediate-risk AML patients into favorable or unfavorable risk groups, which helps doctors make treatment decisions. The test combines cytogenetics, mutation analysis, and expression analysis, and replaces nine separate assays, according to San Diego-based TrovaGene.

Netherlands-based Skyline Diagnostics plans to offer the lab testing services in Europe but expects to eventually expand to other markets, TrovaGene said.

Financial terms of the agreement were not released.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.